Last update: July 6, 2018


Very Low Risk for breastfeeding

Safe. Compatible.
Minimal risk for breastfeeding and infant.

An antihistamine and inhibitor of the release of proinflammatory mediators from mast cells.
Indicated in conjunctivitis and allergic rhinitis.
Topical administration, twice a day.

Since the date of last update, we have not found published data on its excretion in breastmilk.

As in most topical ophthalmological and nasal preparations, the minute dose and its negligible transfer into blood makes it compatible with breastfeeding.
Ophthalmic administration results in plasma concentrations that are very low or below the limit of quantification (EMA 2017, Meier 2017), which makes the transfer in significant amounts to breastmilk very unlikely.
Nasal absorption is greater, similar to oral absorption (57% bioavailability) (Chu 2009).

There are no cumulative effects after multiple doses (Meier 2017, Chu 2009) and side effects are not frequent or serious (EMA 2017).

In ophthalmic administration, absorption can be minimized by pressing a finger on the tear duct (medial canthus of the eye) for 1 minute.


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

オロパタジン塩酸塩 is Olopatadine Hydrochloride in Japanese.

Is written in other languages:


Main tradenames from several countries containing オロパタジン塩酸塩 in its composition:


Variable Value Unit
Oral Bioavail. Oft <1, Nasal 57 %
Molecular weight 374 daltons
Protein Binding 55 %
VD 1,9 l/Kg
Tmax 1 - 2 hours
T1/2 2,9 - 3,4 hours


  1. Meier E, Narvekar A, Iyer GR, DuBiner HB, Vutikullird A, Wirta D, Sall K. Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clin Ophthalmol. 2017 Abstract
  2. EMA. Olopatadine (Opatanol). Drug Summary. 2017 Full text (in our servers)
  3. EMA. Olopatadina (Opatanol). Ficha técnica. 2017 Full text (in our servers)
  4. Chu NN, Chen WL, Xu HR, Li XN. Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Clin Drug Investig. 2009 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM